PACIRA BIOSCIENCES INC (PCRX)
Health Care · Non-opioid pain management biopharmaceuticals · NASDAQ
Pacira BioSciences is a non-opioid pain management company commercializing injectable, device, and gene therapy treatments for postsurgical and osteoarthritis pain.
What PACIRA BIOSCIENCES INC does
Pacira BioSciences is a biopharmaceutical company focused on developing and commercializing non-opioid pain management therapies and regenerative health solutions. Its commercial portfolio features long-acting injectable analgesics for postsurgical pain, extended-release corticosteroid injections for osteoarthritis knee pain, and a drug-free, cold-therapy handheld device for nerve pain. The company is also advancing a gene therapy pipeline for musculoskeletal conditions using a proprietary adenovirus vector platform.
Themes: non-opioid pain management, postsurgical pain, osteoarthritis therapeutics, musculoskeletal pain, gene therapy, regenerative medicine
Fundamentals
- Price$24.67 as of 2026-08-21 close
- Market cap$983M as of 2026-08-21
- 1-year return-2.8% 2025-08-21 close $25.39 → 2026-08-21 close $24.67
- P/E62.71 as of 2026-08-24
- Net margin+2.0% as of 2026-08-24
- Gross margin+79.2% as of 2026-08-24
- ROE+2.1% as of 2026-08-24
- Debt / equity0.54 as of 2026-08-24
- Revenue growth (YoY)+5.7% as of 2026-08-24
- Revenue CAGR (3y)+2.9% SEC XBRL
- Beta0.23 as of 2026-08-24
- Last reported earnings2026-08-04 SEC EDGAR Form 8-K (Item 2.02)
How PCRX compares in its sector
- price-to-earnings ratiotop 25% 203 covered Health Care peers, as of 2026-08-24
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How PACIRA BIOSCIENCES INC looks technically
PACIRA BIOSCIENCES INC (PCRX) is trading 4.3% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 48 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 25 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 50, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 6 trading days ago.
Trend
8
| Distance from the 200-day | it is trading 4.3% above its 200-day average, the long-term trend line — a longer-term uptrend | +4.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $24.86 | $24.86 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $23.65 | $23.65 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 48 trading days ago — a "golden cross", a bullish long-term signal | 48 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 4.3% above | +4.3% |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 25 (a reading of 25+ marks a strong trend) | 24.9 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 50, neither overbought (above 70) nor oversold (below 30) | 49.5 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($22.79 to $27.66) — its "stochastic" reading is 39 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 38.6 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 13 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $27.66 | $27.66 |
|---|---|---|
| From the 52-week high | it is 10.8% below its 52-week high (its highest price of the past year) | -10.8% |
| Above the 52-week low | it is 31.2% above its 52-week low (its lowest price of the past year) | +31.2% |
| Below the 52-week high | it is 10.8% below its highest point of the past year | 10.8% |
| Since a 20-day breakout | it made a new 20-day low about 6 trading days ago | 6 sessions |
| Since a 55-day breakout | it made a new 55-day high about 14 trading days ago | 14 sessions |
| All-time high | its highest closing price on record is $121.95 (set on 2015-02-25) | $121.95 |
| Given back of the 52-week move | over the past year its closes ranged ($19.16 to $27.62), and it has given back roughly a third of its rise from last year’s low — 35% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $22.12 to $22.39. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 34.9% |
| From the all-time high | it is 79.8% below its all-time high | -79.8% |
| Nearest price level | it is sitting right on a resistance level at $24.77 — a price it turned at twice since 2025-11-20, most recently on 2026-07-15. Since 2024-08-21 it has 9 such levels below the current price and 4 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +0.4% |
| All-time low | its lowest closing price on record is $6.16 (set on 2011-02-16) | $6.16 |
| Above the all-time low | it is 300.5% above its all-time low | +300.5% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 98% of the past ~6 months) | 98th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.9452 between its high and its low — about 3.8% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.9452 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $22.28 and $27.91 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $22.28 – $25.09 – $27.91 |
| Typical daily range (% of price) | its price moves about 3.8% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.8% |
| Stretch from the 200-day average | it is trading 1.1 daily ranges above its 200-day average price (4.3% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.1 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.75× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has improved toward "buy" since the prior reading | 0.19 toward buy |
Candlestick patterns
1
| Since a doji | 4 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 4 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.3% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.3% |
|---|---|---|
| Open gap | it gapped 5.7% below the previous close 12 sessions ago and has not traded back through the level it left behind at 27.62 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -5.7% |
| Gap filled | a 3.6% gap up opened on 2026-06-30 has been "filled" 37 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 37 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 6.6 percentage points (the stock lost 4.3% while the market gained 2.3%) | -6.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 2.0 percentage points (the stock gained 5.1% while the market gained 3.1%) | +2.0% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 4.8 percentage points (the stock gained 6.2% while the market gained 11.1%) | -4.8% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 23.3 percentage points (the stock lost 2.8% while the market gained 20.5%) | -23.3% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: MACD momentum is negative, lagging the market over 6 months — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thin, spanning 1.8% of the share price, which is taken to mean a barrier that gives way easily. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 6% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $23.25 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +6.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is sitting right on the average price paid since it last reported on 2026-08-04 (its 10-Q), so the typical buyer over that stretch is roughly break-even. That average is $24.62 — a volume-weighted average of daily closes over 14 sessions, not a true tick-by-tick VWAP. | +0.2% |
Price levels it has turned at before
PCRX last closed at $24.67 on 2026-08-21. Since 2024-08-21 it has turned at 9 prices below its last close and 4 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $24.77 | Resistance | 0.4% above the last close | turned there twice · 2025-11-20 to 2026-07-15 |
| $25.36 | Resistance | 2.8% above the last close | turned there five times · 2025-05-29 to 2026-05-27 |
| $23.84 | Support | 3.4% below the last close | turned there 7 times · 2025-06-12 to 2026-06-11 |
| $22.95 | Support | 7.0% below the last close | turned there four times · 2025-05-09 to 2026-08-14 |
| $26.93 | Resistance | 9.2% above the last close | turned there five times · 2025-05-21 to 2026-07-07 |
| $21.92 | Support | 11.2% below the last close | turned there six times · 2025-03-12 to 2026-06-22 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · Trading inside the Ichimoku cloud · Near a resistance level (pressing into a price that has capped it before) | Learn: moving average · golden cross · adx · rsi · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.14 mean, 1=Strong Buy…5=Strong Sell) — 7 analysts
- Mean price target$30.00 range $23.00 – $38.00
Analyst estimates, as of 2026-08-23. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for PCRX
- Consensus EPS estimate$0.712 next reporting period, as of 2026-08-23
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Continued dependence on three primary commercial products (EXPAREL, ZILRETTA, iovera°) for revenue generation, with limited near-term product diversification","Clinical development risk on PCRX-201 gene therapy and other pipeline programs; failure to advance or obtain regulatory approval could impact long-term growth","Competitive pressure from opioid and non-opioid pain management alternatives from larger pharmaceutical competitors"]
What changed in the latest 10-Q
AI-assisted comparison of PCRX's 10-Q filed 2026-04-30 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Added reference to 'PCRX-2002' as a product candidate in forward-looking statements (filed 2026-04-30)
- Added reference to 'high-capacity adenovirus ("HCAd") vector platform' in forward-looking statements (filed 2026-04-30)
- Added statement 'The forward-looking statements included in this Quarterly Report on Form 10-Q represent our views as of the filing date of this Quarterly Report on Form 10-Q.' (filed 2026-04-30)
- Added narrative section clarifying company focus on 'two therapeutic areas' with explicit mention of 'postsurgical pain control' and 'early intervention osteoarthritis, or OA, pain management' (filed 2026-04-30)
- Added description of ZILRETTA as 'extended-release corticosteroid' with 'single injection' language and direct comparison to alternatives (filed 2026-04-30)
- Removed:
- Removed reference to 'the expected cost savings and benefits of a July 2025 reduction in force' from forward-looking statements (filed 2025-11-06)
- Removed statement 'the failure to realize the anticipated benefits and synergies from the acquisition of GQ Bio Therapeutics GmbH' from risk factors (filed 2025-11-06)
- Removed reference to 'multivesicular liposome, or pMVL, drug delivery technology' in product development forward-looking statements; changed to 'high-capacity adenovirus ("HCAd") vector platform' (filed 2026-04-30)
- Removed reference to '2024 Annual Report'; changed to '2025 Annual Report' (filed 2026-04-30)
- Removed reference to 'Part II. Item 1A in this Quarterly Report on Form 10-Q' from risk factors disclosure (filed 2026-04-30)
- Removed narrative details about acquisition dates and history (Flexion Acquisition in November 2021, MyoScience Acquisition in April 2019) (filed 2026-04-30)
- Removed statement that 'there is no product held by wholesalers' regarding EXPAREL drop-shipping (filed 2026-04-30)
- Removed reference to ZILRETTA as 'first and only extended-release, intra-articular, or IA, injectable therapy' (filed 2026-04-30)
- Reworded:
- Changed product development technology reference from 'pMVL-based product' to 'HCAd-based product candidate' in forward-looking statements (filed 2026-04-30)
- Changed reference from 'including PCRX-201 (enekinragene inzadenovec)' to 'including, but not limited to, PCRX-201 (enekinragene inzadenovec) and PCRX-2002' (filed 2026-04-30)
- Restructured Overview section to present company focus in 'two therapeutic areas' framework rather than sequential product descriptions (filed 2026-04-30)
- Changed EXPAREL description from 'long-acting, local analgesic' with pMVL technology explanation to integration of therapy type with clinical use context (filed 2026-04-30)
- Simplified ZILRETTA introduction by removing 'first and only' superlative and acquisition context (filed 2026-04-30)
- Changed ZILRETTA benefit duration reference from 'three months' to explicit 'three months of relief' (filed 2026-04-30)
- Notes:
- The newer filing text appears truncated at the end of the Overview section, limiting full comparison of that section
- The older filing text also appears truncated, limiting complete assessment of all changes
- Page number changed from 37 to 30, consistent with different filing periods (Q3 2025 vs Q1 2026)
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 2 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 2 sells ($372170) — 2 selling insiders
- Last 180 days0 buys · 6 sells ($1M) — 3 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-06-11. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about PCRX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding PCRX as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 11,371,216
- Reported value $256,989,480
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
PCRX had 7,212,032 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
PCRX had 18.1% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 13.39 days to cover at the same settlement.
- Reported short interest (shares) 7,212,032
- Short interest (% of shares outstanding) 18.1%
- Prior settlement (shares) 6,963,375
- Reported change 3.57%
- Days to cover (reported) 13.39
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Heron Therapeutics (HRTX)
- Pinnacle Spine Group
- DJO Global
- Smith & Nephew
- Stryker (SYK)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare PCRX vs…
PACIRA BIOSCIENCES INC is found in…
Frequently asked questions
What does PACIRA BIOSCIENCES INC (PCRX) do?
Pacira BioSciences is a biopharmaceutical company focused on developing and commercializing non-opioid pain management therapies and regenerative health solutions. Its commercial portfolio features long-acting injectable analgesics for postsurgical pain, extended-release corticosteroid injections for osteoarthritis knee pain, and a drug-free, cold-therapy handheld device for nerve pain.
What sector is PACIRA BIOSCIENCES INC (PCRX) in?
PACIRA BIOSCIENCES INC (PCRX) is classified in the Health Care sector. Its industry is Non-opioid pain management biopharmaceuticals. It trades on NASDAQ.
Who are PACIRA BIOSCIENCES INC's (PCRX) competitors?
Notable peers of PACIRA BIOSCIENCES INC (PCRX) include Heron Therapeutics, Pinnacle Spine Group, DJO Global, Smith & Nephew and Stryker. This peer set is informational only — not financial advice.
Is PACIRA BIOSCIENCES INC (PCRX) overbought or oversold right now?
PACIRA BIOSCIENCES INC (PCRX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 50, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on PCRX come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.